Dr Klempner and the Oncology Brothers discuss the treatment paradigm for patients with metastatic upper GI cancers.
Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups
Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases
Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC
Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Cabozantinib Earns CHMP Recommendation in Pancreatic Neuroendocrine Tumors
Data from the phase 3 CABINET trial support the CHMP’s positive opinion of cabozantinib in well-differentiated extrapancreatic or pancreatic NETs.